Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Adjuvant Candidate Discovery for Cancer Vaccine


As a global leader in cancer vaccine services, Creative Biolabs provides adjuvant discovery services for cancer vaccines to meet our clients’ requirements. To support adjuvant services, we also provide adjuvant synthesis services including aluminum, bacterial products, oil Adjuvant, and ISCOMS, etc. As a key component to enhance the immune response to tumor antigens, our adjuvant discovery services will help you obtain a more efficient vaccine coupled with optimal adjuvants.


Adjuvants can be added to the vaccines as immune agents to enhance the immune response. The mechanism of adjuvant relies on higher antibody production and longer protection. Here are different ways regarding the mechanisms.

  • By extending the presence of antigen in the blood to expand vaccine protection;
  • By helping bind the antigens of antigen presenting cells to improve the immune response;
  • By supporting the production of cytokines;
  • By activating lymphocytes and macrophages.

General mode of action of an adjuvant. Fig.1 General mode of action of adjuvants. (Garçon, 2017)

Our Capabilities
For discovering the most promising adjuvant candidate used for cancer vaccine to enhance the immune response.

With the goal of supporting the screening and identification for new vaccine adjuvant candidates against cancer, Creative Biolabs has developed comprehensive adjuvant discovery services including:

  • Identification of novel adjuvant candidates via high throughput screening;
  • Validation of adjuvant candidates through stimulating immune cells;
  • Determination of the mechanism of action (MoA) of adjuvant candidates, including identification of the targeting receptor and the cellular signaling pathway;
  • Optimization of adjuvant candidates via formulation development and medicinal chemistry;
  • Verification of the efficacy of adjuvants in animal models.

With years of exploration, we have accumulated extensive experience in a wide range of adjuvant types covering:

  • Mineral Salt Adjuvant

Mineral salts include insoluble aluminum salts and calcium phosphate, which have been used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants have been used to help induce early, high-titer, and long-lasting immunity response. Aluminum compounds, including aluminum hydroxy phosphate, aluminum oxyhydroxide, amorphous aluminum hydroxy phosphate sulfate, and alum-precipitated vaccines, are commonly used adjuvants. Over the years, we have focused on the mineral salt-based adjuvants, and our experts will help you develop the mineral salt adjuvants for cancer vaccines.

  • Oil Adjuvant

Oil adjuvants are also known as emulsion adjuvants (either oil-in-water or water-in-oil). Oil adjuvants show wide and diverse potential in vaccine development due to the obvious effects of emulsions as carriers of cancer vaccines and immune-stimulatory molecules. We are confident to provide our clients with oil adjuvant discovery services.

  • Saponin Adjuvant

As natural glycosides of steroid or triterpene, saponins are widely distributed in the plant and play different biological and pharmacological activities including anti-inflammatory, cytotoxic, anti-allergic, anti-tumor, and anti-tumor-promoting, anti-virus, etc. They can be used in vaccines as immune adjuvants. Our scientists are can help you with the saponin adjuvant discovery services.

  • Lipopolysaccharide

For decades, we have focused on the lipopolysaccharide and its derivative, monophosphorylated lipid A. With extensive experience and advanced platforms. We can help you with the discovery and development of the lipopolysaccharides or monophosphorylated lipid A for cancer vaccines.

  • CpG

As a higher frequency of unmethylated deoxycytidyl-deoxyguanosine dinucleotides identified in the bacterial genome, CpG can mimic the immunostimulatory activity with small oligodeoxynucleotides (ODN). We offer CpG-ODNs adjuvant discovery services to facilitate your cancer vaccine development.

  • Bacteria-derived Adjuvant

Appropriate bacterial-derived adjuvants can help to induce a stronger immune response to provide better, longer-lasting protection against cancer. Our experts will help to develop the bacteria-derived adjuvants to facilitate your cancer vaccine.

  • Adjuvant Emulsions

Adjuvant emulsions can help capture antigens that can support slow release to stimulate the immune system. Also, they can enhance antigen persistence and increase APC recruitment and activation. We are committed to offering adjuvant emulsions to facilitate optimization of your cancer vaccine.


With extensive adjuvants discovery services and expertise, we help our clients successfully launch the cancer vaccine discovery to boost the development process. Our unique features will ensure you a perfect adjuvant candidate for a specific cancer vaccine.

  • Customized services: a wide range of screening parameters will be designed to meet our clients’ requirements;
  • Short turnaround time;
  • Competitive price with superior quality.

With comprehensive expertise and advanced platforms for various adjuvants, Creative Biolabs is dedicated to providing adjuvant candidate discovery and selection services and products. To drive your cancer vaccine projects, we are committed to offering the best solutions to customize the customer's proven satisfactory service. If you are interested in our services, please feel free to contact us to learn how we can be involved in your cancer vaccine projects.


  1. Garçon, Nathalie, and Alberta Di Pasquale. "From discovery to licensure, the adjuvant system story." Human vaccines & immunotherapeutics 13.1 (2017): 19-33.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.